望石智慧 （StoneWise）

StoneWise's small-molecule early-discovery agent MolVortex has completed local deployment on Lianyungang's "AI + medicine" public service platform and been listed in its AI tool marketplace, open to local pharma companies, hospital researchers, universities and innovation service providers. The platform, invested in and built by Jiangsu XinHailian Group, went live at the 8th Lianyungang Pharmaceutical Technology Conference, aiming to let companies call AI capabilities and data assets on demand without building their own compute facilities. MolVortex covers target research, pocket analysis, molecule generation and dynamics evaluation across the early-discovery path from hit to preclinical candidate.

StoneWise's small-molecule early-discovery agent MolVortex has completed local deployment on Lianyungang's "AI + medicine" public service platform and been listed in its AI tool marketplace, open to local pharma companies, hospital researchers, universities and innovation service providers. The platform, invested in and built by Jiangsu XinHailian Group, went live at the 8th Lianyungang Pharmaceutical Technology Conference, aiming to let companies call AI capabilities and data assets on demand without building their own compute facilities. MolVortex covers target research, pocket analysis, molecule generation and dynamics evaluation across the early-discovery path from hit to preclinical candidate.